Top

Current Sexual Health Reports

Published in:

01-12-2020 | Erectile Dysfunction | Medical Comorbidities (J Kovac & O Raheem, Section Editors)

Male Sexual Health and Cardiovascular Disease

Authors: Garrick M. Greear, Nishant Garg, Tung-Chin Hsieh

Published in: Current Sexual Health Reports | Issue 4/2020

Abstract

Purpose of Review

To provide an updated review on the association of erectile dysfunction (ED), male hypogonadism, and testosterone therapy with cardiovascular disease (CVD).

Recent Findings

Direct evidence links male sexual dysfunction to CVD, including higher coronary artery calcium scores, carotid narrowing, and more severe coronary artery disease. While questions about the role of ED in predicting cardiovascular risk independent of shared comorbidities have lingered, the most recent analyses favor a diagnosis of ED as a strong independent predictor of adverse cardiac events. ED has now been incorporated into the widely used QRISK3 calculator for cardiovascular risk assessment and may influence clinical decision-making about primary prevention interventions. Controversy also surrounds changes in testosterone labeling that highlight potential cardiovascular risks. While continuing to remain contentious, the most extensive meta-analyses conclude that low endogenous testosterone is independently associated with increased cardiovascular risk and that testosterone therapy does not appear to carry increased risk in most populations.

Summary

The assessment of ED is an effective tool in predicting cardiovascular risk and may influence clinical decision-making with regard to primary prevention interventions. The associations between endogenous testosterone levels, testosterone therapy, and cardiovascular risk remain controversial.

Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev Med. 2000;30(4):328–38.PubMed

Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. John Wiley & Sons, Ltd. 1999;84(1):50–6.PubMed

Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. John Wiley & Sons, Ltd. 2007;61(12):2019–25.PubMed

Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;1(8422):181–4.PubMed

Montorsi F, Briganti A, Salonia A, Rigatti P, Margonato A, Macchi A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. Elsevier. 2003;44(3):360–5.PubMed

Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, Briganti A, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27(22):2632–9.PubMed

Montorsi P, Ravagnani PM, Galli S, Rotatori F, Briganti A, Salonia A, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(12B):19M–23M.PubMed

Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43(2):179–84.PubMed

• Orimoloye OA, Feldman DI, Blaha MJ. Erectile dysfunction links to cardiovascular disease-defining the clinical value. Trends Cardiovasc Med. 2019;29(8):458–65. Excellent review from a cardiovascular perspective highlighting potential improvements to current screening algorithms by incorporating the presence or absence of erectile dysfunction.PubMed

10.

Chiurlia E, D'Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol. 2005;46(8):1503–6.PubMed

11.

• Schönhofen J, Mohan V, Schumacher MC, Bechir M, Keo HH, Schönhofen H, et al. Incidental findings during computed tomographic angiography diagnostic work-up in patients with arteriogenic erectile dysfunction. Swiss Med Wkly. 2019;149(4950):w20154. EMH Media. Important study that illustrates the importance of discussing cardiovascular risk in patients with erectile dysfunction who have not undergone a cardiovascular risk assessment.PubMed

12.

Feldman DI, Cainzos-Achirica M, Billups KL, DeFilippis AP, Chitaley K, Greenland P, et al. Subclinical vascular disease and subsequent erectile dysfunction: the multiethnic study of atherosclerosis (MESA). Clin Cardiol. 2016;39(5):291–8.PubMedPubMedCentral

13.

Yaman O, Gulpinar O, Hasan T, Ozdol C, Ertas FS, Ozgenci E. Erectile dysfunction may predict coronary artery disease: relationship between coronary artery calcium scoring and erectile dysfunction severity. Int Urol Nephrol. 2008;40(1):117–23.PubMed

14.

Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med. 2004;164(12):1285–92.PubMed

15.

Dong J-Y, Zhang Y-H, Qin L-Q. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol. 2011;58(13):1378–85.PubMed

16.

Zhao B, Hong Z, Wei Y, Yu D, Xu J, Zhang W. Erectile dysfunction predicts cardiovascular events as an independent risk factor: a systematic review and meta-analysis. J Sex Med. 2019;16(7):1005–17.PubMed

17.

Araujo AB, Hall SA, Ganz P, Chiu GR, Rosen RC, Kupelian V, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? J Am Coll Cardiol. 2010;55(4):350–6.PubMedPubMedCentral

18.

Uddin SMI, Mirbolouk M, Dardari Z, Feldman DI, Cainzos-Achirica M, DeFilippis AP, et al. Erectile dysfunction as an independent predictor of future cardiovascular events. Circulation. Lippincott Williams & Wilkins Hagerstown, MD. 2018;138(5):540–2.PubMed

19.

• Al-Daydamony MM, Shawky A, Tharwat A. Erectile dysfunction severity as a predictor of left main and/or three-vessel disease in acute coronary syndrome patients. Indian Heart J. 2018;70(Suppl 3):S56–9. Provocative study that further reinforces the association between erectile dysfunction and cardiovascular disease by demonstrating that there is a positive correlation between severity of erectile dysfunction and severity of coronary artery disease.PubMedPubMedCentral

20.

Raheem OA, Su JJ, Wilson JR, Hsieh T-C. The association of erectile dysfunction and cardiovascular disease: a systematic critical review. Am J Mens Health. SAGE PublicationsSage CA: Los Angeles, CA. 2017;11(3):552–63.PubMed

21.

Pastuszak AW, Hyman DA, Yadav N, Godoy G, Lipshultz LI, Araujo AB, et al. Erectile dysfunction as a marker for cardiovascular disease diagnosis and intervention: a cost analysis. J Sex Med. 2015;12(4):975–84.PubMedPubMedCentral

22.

Barrett-Connor E. Cardiovascular risk stratification and cardiovascular risk factors associated with erectile dysfunction: assessing cardiovascular risk in men with erectile dysfunction. Clin Cardiol. 2004;27(4 Suppl 1):I8–13.PubMed

23.

•• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099. British Medical Journal Publishing Group. One of the first widely used cardiovascular risk calculators to incorporate the diagnosis of erectile dysfunction as an independent predictor of future adverse cardiac events.PubMedPubMedCentral

24.

Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2935–59.PubMed

25.

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. Lippincott Williams & Wilkins Hagerstown, MD. 2019;140(11):e596–646.PubMedPubMedCentral

26.

Miner M, Parish SJ, Billups KL, Paulos M, Sigman M, Blaha MJ. Erectile dysfunction and subclinical cardiovascular disease. Sex Med Rev. 2019;7(3):455–63.PubMed

27.

Biebel MG, Burnett AL, Sadeghi-Nejad H. Male sexual function and smoking. Sex Med Rev. 2016;4(4):366–75.PubMed

28.

Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. American Medical Association. 2004;291(24):2978–84.PubMed

29.

Khatana SAM, Taveira TH, Miner MM, Eaton CB, Wu W-C. Does cardiovascular risk reduction alleviate erectile dysfunction in men with type II diabetes mellitus? Int J Impot Res. 2008;20(5):501–6.PubMed

30.

• Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med. 2014;11(7):1626–35. Statins are a critical medication in primary prevention of adverse cardiovascular events and these important findings (no overall change in erectile function with statin therapy) should be relayed to patients who are concerned about any possible adverse impact of statin therapy on sexual function.PubMed

31.

Burnett AL, Nehra A, Breau RH, Culkin DJ, Faraday MM, Hakim LS, et al. Erectile dysfunction: AUA guideline. J Urol. Wolters KluwerPhiladelphia, PA. 2018;200(3):633–41.PubMed

32.

Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore longitudinal study of aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2001;86(2):724–31.PubMed

33.

Grossmann M, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab. 2017;102(3):1067–75.PubMedPubMedCentral

34.

Giagulli VA, Castellana M, Carbone MD, Pelusi C, Ramunni MI, De Pergola G, et al. Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism. Andrology. 2020;102:1067.

35.

Travison TG, Shackelton R, Araujo AB, Hall SA, Williams RE, Clark RV, et al. The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc. John Wiley & Sons, Ltd. 2008;56(5):831–9.PubMedPubMedCentral

36.

Luria MH, Johnson MW, Pego R, Seuc CA, Manubens SJ, Wieland MR, et al. Relationship between sex hormones, myocardial infarction, and occlusive coronary disease. Arch Intern Med. 1982;142(1):42–4.PubMed

37.

Lichtenstein MJ, Yarnell JW, Elwood PC, Beswick AD, Sweetnam PM, Marks V, et al. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol. 1987;126(4):647–57.PubMed

38.

Khaw KT, Barrett-Connor E. Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arterioscler Thromb. 1991;11(3):489–94.PubMed

39.

Phillips GB. Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci U S A. National Academy of Sciences. 1977;74(4):1729–33.PubMedPubMedCentral

40.

Gyllenborg J, Rasmussen SL, Borch-Johnsen K, Heitmann BL, Skakkebaek NE, Juul A. Cardiovascular risk factors in men: the role of gonadal steroids and sex hormone-binding globulin. Metab Clin Exp. 2001;50(8):882–8.PubMed

41.

Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14(5):701–6.PubMed

42.

Khaw K-T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. Lippincott Williams & Wilkins. 2007;116(23):2694–701.PubMed

43.

Adelborg K, Rasmussen TB, Nørrelund H, Layton JB, Sørensen HT, Christiansen CF. Cardiovascular outcomes and all-cause mortality following measurement of endogenous testosterone levels. Am J Cardiol. 2019;123(11):1757–64.PubMed

44.

Ruige JB, Mahmoud AM, De Bacquer D, Kaufman J-M. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. BMJ Publishing Group Ltd. 2011;97(11):870–5.PubMed

45.

•• Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15(9):1260–71. A recent well-conceived and well-executed meta-analysis on the association between low endogenous testosterone and increased cardiovascular risk.PubMed

46.

Baillargeon J, Kuo Y-F, Westra JR, Urban RJ, Goodwin JS. Testosterone prescribing in the United States, 2002-2016. JAMA. American Medical Association. 2018;320(2):200–2.PubMedPubMedCentral

47.

Morden NE, Woloshin S, Brooks CG, Schwartz LM. Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. JAMA Intern Med. 2019;179(3):446–8.PubMed

48.

Seftel AD. Re: testosterone products: drug safety communication - FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke. J Urol. 2015;194(3):759–60.PubMed

49.

Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.PubMedPubMedCentral

50.

Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36.PubMed

51.

Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. Gong Y, editor. PLoS One. Public Library of Science. 2014;9(1):e85805.PubMedPubMedCentral

52.

Traish AM, Guay AT, Morgentaler A. Death by testosterone? We think not! J Sex Med. 2014;11(3):624–9.PubMed

53.

Corona G, Rastrelli G, Guaraldi F, Tortorici G, Reismann Y, Sforza A, et al. An update on heart disease risk associated with testosterone boosting medications. Expert Opin Drug Saf. 2019;18(4):321–32.PubMed

54.

•• Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Testosterone and cardiovascular risk: meta-analysis of interventional studies. J Sex Med. 2018;15(6):820–38. Another excellent meta-analysis conducted by Corona et al. evaluating all pharmaco-epidemiological and interventional testosterone therapy trials.PubMed

55.

A study to evaluate the effect of testosterone replacement therapy (TRT) on the incidence of major adverse cardiovascular events (MACE) and efficacy measures in hypogonadal men (TRAVERSE). In: National Institutes of Health, National Library of Medicine, ClinicalTrials.gov. 2020. https://clinicaltrials.gov/ct2/show/NCT03518034. Accessed 17 January 2020.

56.

Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6(1):77–85.PubMed

57.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.PubMed

58.

Ajayi AA, Mathur R, Halushka PV. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation. Lippincott Williams & Wilkins. 1995;91(11):2742–7.PubMed

59.

Finkelstein JS, Lee H, Burnett-Bowie S-AM, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–22.PubMedPubMedCentral

60.

Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. American Medical Association. 2017;317(7):708–16.PubMedPubMedCentral

61.

Walker RF, Zakai NA, MacLehose RF, Cowan LT, Adam TJ, Alonso A, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med. American Medical Association. 2019;180(2):190–7.PubMedCentral

62.

Yassin A, Haider A, Haider KS, Caliber M, Doros G, Saad F, et al. Testosterone therapy in men with Hypogonadism prevents progression from Prediabetes to type 2 diabetes: eight-year data from a registry study. Diabetes Care. 2019;42(6):1104–11.PubMed

63.

Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail. John Wiley & Sons, Ltd. 2007;9(1):44–50.PubMed

64.

Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–27.PubMed

65.

Yu J, Akishita M, Eto M, Ogawa S, Son B-K, Kato S, et al. Androgen receptor-dependent activation of endothelial nitric oxide synthase in vascular endothelial cells: role of phosphatidylinositol 3-kinase/akt pathway. Endocrinology. 2010;151(4):1822–8.PubMed

66.

Yoshida S, Aihara K-I, Ikeda Y, Sumitomo-Ueda Y, Uemoto R, Ishikawa K, et al. Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling. Circulation. Lippincott Williams & Wilkins Hagerstown, MD. 2013;128(1):60–71.PubMedPubMedCentral

67.

Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99(13):1666–70.PubMed

68.

English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. Lippincott Williams & Wilkins. 2000;102(16):1906–11.PubMed

69.

Tirabassi G, Cignarelli A, Perrini S, Delli Muti N, Furlani G, Gallo M, et al. Influence of CAG repeat polymorphism on the targets of testosterone action. Int J Endocrinol. Hindawi. 2015;2015(2):298107–12.PubMedPubMedCentral

Title: Male Sexual Health and Cardiovascular Disease
Authors: Garrick M. Greear
Nishant Garg
Tung-Chin Hsieh
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Erectile Dysfunction
Testosterone
Hypogonadism
Published in: Current Sexual Health Reports / Issue 4/2020
Print ISSN: 1548-3584
Electronic ISSN: 1548-3592
DOI: https://doi.org/10.1007/s11930-020-00281-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Male Sexual Health and Cardiovascular Disease

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

Zero Tolerance for Genital Mutilation: a Review of Moral Justifications

It Is Time We Rethink Our Approach to Enhancing Access to Male Infertility Care

Rethinking the Anti-FGM Zero-Tolerance Policy: from Intellectual Concerns to Empirical Challenges

Different Cultures but Similar Requests: Adolescents’ Demands for Non-therapeutic Genital Modifications

Critical Discussion on Female Genital Cutting/Mutilation and Other Genital Alterations

Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction